Research programme: urological disorder therapeutics - IXALTISAlternative Names: IXA-002; IXA-003
Latest Information Update: 06 Jun 2016
At a glance
- Originator Sanofi-Synthelabo
- Developer IXALTIS
- Mechanism of Action Monoamine oxidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Genitourinary disorders